Global In-Silico Drug Discovery Market: Focus on Products, Technologies, Workflow, End Users, Country Data (17 Countries), and Competitive Landscape - Analysis and Forecast, 2018-2029

1.1 Inclusion and Exclusion

2.1 Scope of the Study
2.2 Key Questions Answered in the Report

3.1 Global In-Silico Drug Discovery Market: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model

4.1 Regulatory Framework
4.1.1 Regulatory Framework in North America
4.1.2 Regulatory Framework in Europe
4.1.3 Regulatory Framework in Asia-Pacific

5.1 Mergers and Acquisitions
5.2 Product Launches and Product Updates
5.3 Synergistic Activities
5.4 Business Expansion Activities and Others
5.5 Market Share Analysis

6.1 Overview
6.2 Impact Analysis
6.3 Market Drivers
6.3.1 Emphasis on Reduction in Medical Errors and Readmission Rates
6.3.2 Growth in the Biomarker Identification Market and Advancements in In-Silico Drug Discovery Techniques
6.3.3 Technological Advancements in the Field of Computational Biology
6.4 Market Restraints
6.4.1 Lack of High Complexity Testing Centers
6.4.2 Expensive Procedures and Their Applications in Medical Treatments
6.4.3 High Capital Requirement Hampering the Expansion of Global Reach
6.5 Market Opportunities
6.5.1 Massive Scope for Adoption of In-Silico drug discovery in Developing Nations
6.5.2 Integration of Blockchain Technology in Interoperability
6.5.3 Collaborations with Precision Medicine Providers

7.1 Introduction
7.2 Market Availability for In-Silico Drug Discovery
7.3 In-Silico Drug Discovery Market Technology Trends

8.1 Overview
8.2 Discovery
8.2.1 Target Identification
8.2.1.1 Bioinformatics
8.2.1.2 Reverse Docking
8.2.1.3 Protein Structure Prediction
8.2.2 Target Validation
8.2.3 Lead Discovery
8.2.3.1 Library Design
8.2.3.2 Pharmacophore
8.3 Pre-Clinical Tests
8.4 Clinical Trials

9.1 Software
9.2 Software as a Service (Cloud)
9.3 Consultancy as a Service

10.1 Molecular Modeling and de Novo Drug Design Software
10.2 Pharmacophore Modeling Software

11.1 Contract Research Organizations
11.2 Pharmaceutical Industry
11.3 Academic and Research Institutes
11.4 Other End Users (Hospitals and Other Care Facilities)

12.1 Overview
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 France
12.3.3 U.K.
12.3.4 Italy
12.3.5 Spain
12.3.6 Russia
12.3.7 Rest-of-Europe
12.4 Asia-Pacific
12.4.1 China
12.4.2 Japan
12.4.3 Australia
12.4.4 India
12.4.5 South Korea
12.4.6 Rest-of-APAC
12.5   Latin America
12.5.1 Brazil
12.5.2 Mexico
12.6   Rest-of-the-World

13.1 Overview
13.2 Albany Molecular Research Inc.
13.2.1 Company Overview
13.2.2 Role of Albany Molecular Research Inc.in the Global In-Silico Drug Discovery Market
13.2.3 SWOT Analysis
13.3 Certara USA, Inc.
13.3.1 Company Overview
13.3.2 Role of Certara USA, Inc. in the Global In-Silico Drug Discovery Market
13.3.3 SWOT Analysis
13.4 Charles River
13.4.1 Company Overview
13.4.2 Role of Charles River in the Global In-Silico Drug Discovery Market
13.4.3 Financials
13.4.4 SWOT Analysis
13.5 Chemical Computing Group ULC
13.5.1 Company Overview
13.5.2 Role of Chemical Computing Group ULC in the Global In-Silico Drug Discovery Market
13.5.3 SWOT Analysis
13.6 Collaborative Drug Discovery Inc.
13.6.1 Company Overview
13.6.2 Role of Collaborative Drug Discovery Inc., in the Global In-Silico Drug Discovery Market
13.6.3 SWOT Analysis
13.7 Dassault System (Biovia)
13.7.1 Company Overview
13.7.2 Role of Dassault System (Biovia) in the Global In-Silico Drug Discovery Market
13.7.3 SWOT Analysis
13.8 Evotec A.G.
13.8.1 Company Overview
13.8.2 Role of Evotec A.G. Company in the Global In-Silico Drug Discovery Market
13.8.3 Financials
13.8.4 Key Insights About Financial Health of the Company
13.8.5 SWOT Analysis
13.9 GVK Biosciences Private Limited
13.9.1 Company Overview
13.9.2 Role of GVK Biosciences Private Limited in the Global In-Silico Drug Discovery Market
13.9.3 SWOT Analysis
13.10   ICAGEN, INC.
13.10.1 Company Overview
13.10.2 Role of ICAGEN, INC. in the Global In-Silico Drug Discovery Market
13.10.3 Financials
13.10.4 Key Insights About Financial Health of the Company
13.10.5 SWOT Analysis
13.11   Novo Informatics Pvt. Ltd.
13.11.1 Company Overview
13.11.2 Role of Novo Informatics Pvt. Ltd. in the Global In-Silico Drug Discovery Market
13.11.3 SWOT Analysis
13.12   Numerate, Inc.
13.12.1 Company Overview
13.12.2 Role of Numerate Inc. in the Global In-Silico Drug Discovery Market
13.12.3 SWOT Analysis
13.13   PerkinElmer, Inc.
13.13.1 Company Overview
13.13.2 Role of PerkinElmer Inc, in Global In-Silico Drug Discovery Market
13.13.3 Financials
13.13.4 Key Insights About Financial Health of the Company
13.13.5 SWOT Analysis
13.14   Schrödinger, LLC
13.14.1 Company Overview
13.14.2 Role of Schrödinger, LLC in the Global In-Silico Drug Discovery Market
13.14.3 SWOT Analysis
13.15   Selvita
13.15.1 Company Overview
13.15.2 Role of Selvita in the Global In-Silico Drug Discovery Market
13.15.3 SWOT Analysis
13.16   Simulation Plus
13.16.1 Company Overview
13.16.2 Role of Simulation Plus in the Global In-Silico Drug Discovery Market
13.16.3 Financials
13.16.4 Key Insights About Financial Health of the Company
13.16.5 SWOT Analysis
13.17   WuXi AppTec
13.17.1 Company Overview
13.17.2 Role of WuXi AppTec in the Global In-Silico Drug Discovery Market
13.17.3 Financials
13.17.4 Key Insights About Financial Health of the Company
13.17.5 SWOT Analysis
13.18   e-therapeutics plc (Snapshot)
13.18.1 Company Overview
13.18.2 Role of e-therapeutics plc in the Global In-Silico Drug Discovery Market
13.18.3 Financials

Table 4.1: Regulatory Framework for In-Silico Drug Discovery Market in North America
Table 4.2: Regulatory Framework for In-Silico Drug Discovery Market in Europe
Table 4.3: Regulatory Framework for In-Silico Drug Discovery Market in Asia-Pacific
Table 6.1: Country-Wise Analysis of Adverse Events, 2016

Figure 1: Cost-Benefit Analysis between Conventional and In-Silico Method
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global In-Silico Drug Discovery Market
Figure 3: Global In-Silico Drug Discovery Market, by Workflow, 2018 vs. 2029 ($Million)
Figure 4: Global In-Silico Drug Discovery Market, by Product, 2018 vs. 2029 ($Million)
Figure 5: Global In-Silico Drug Discovery Market, by Software Type, 2018 vs. 2029 ($Million)
Figure 6: Global In-Silico Drug Discovery Market, by End User, 2018 vs. 2029 ($Million)
Figure 7: Global In-Silico Drug Discovery Market Snapshot
Figure 2.1: Global In-Silico Drug Discovery Market Segmentation
Figure 3.1: Global In-Silico Drug Discovery Market Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 5.1: Share of Key Developments and Strategies, January 2016–June 2019
Figure 5.2: Product Launches Share (by Company), January 2016–December 2019
Figure 5.3: Synergistic Activities Share (by Company), January 2016–December 2019
Figure 5.4: Business Expansion Activities Share (by Company), January 2016–December 2019
Figure 5.5: Market Share Analysis for the In-Silico Drug Discovery Market, 2018
Figure 6.1: Impact Analysis
Figure 7.1: Different Steps in the In-Silico Drug Discovery Process
Figure 8.1: Global In-Silico Drug Discovery Market (by Workflow)
Figure 8.2: Global In-Silico Drug Discovery Market (by Workflow), 2018-2029
Figure 8.3: Global In-Silico Drug Discovery Market (Target Identification), 2018-2029
Figure 8.4: Global In-Silico Drug Discovery Market (Bioinformatics), 2018-2029
Figure 8.5: Global In-Silico Drug Discovery Market (Reverse Docking), 2018-2029
Figure 8.6: Global In-Silico Drug Discovery Market (Protein Structure Prediction), 2018-2029
Figure 8.7: Global In-Silico Drug Discovery Market (Target Validation), 2018-2029
Figure 8.8: Global In-Silico Drug Discovery Market (Lead Discovery), 2018-2029
Figure 8.9: Global In-Silico Drug Discovery Market (Library Design), 2018-2029
Figure 8.10: Global In-Silico Drug Discovery Market (Pharmacophore), 2018-2029
Figure 8.11: Global In-Silico Drug Discovery Market (Pre-Clinical Tests), 2018-2029
Figure 8.12: Global In-Silico Drug Discovery Market (Clinical Trials), 2018-2029
Figure 9.1: Global In-Silico Drug Market (Software), 2018-2029
Figure 9.2: Global In-Silico Drug Market (Software as a Service), 2018-2029
Figure 9.3: Global Molecular In-Silico Drug Discovery Market (Consultancy as a Service), 2018-2029
Figure 10.1: Global In-Silico Drug Discovery Market (by Molecular Modeling and de Novo Drug Design Software), 2018-2029
Figure 10.2: Global In-Silico Drug Market (Pharmacophore Modeling Software), 2018-2029
Figure 11.1: Global In-Silico Drug Discovery Market (Contract Research Organizations), 2018-2029
Figure 11.2: Global In-Silico Drug Discovery Market (Pharmaceutical Industry), 2018-2029
Figure 11.3: Global In-Silico Drug Discovery Market (Academic and Research Institutes), 2018-2029
Figure 11.4: Global In-Silico Drug Discovery Market (Hospitals and Other Care Facilities), 2018-2029
Figure 12.1: Global In-Silico Drug Discovery Market (by Region)
Figure 12.2: Global In-Silico Drug Discovery Market (by Region), 2018-2029
Figure 12.3: Global In-Silico Drug Discovery Market Share (by Region), 2018
Figure 12.4: Global In-Silico Drug Discovery Market Share (by Region), 2029
Figure 12.5: North America In-Silico Drug Discovery Market, 2018-2029
Figure 12.6: North America: Market Dynamics
Figure 12.7: North America In-Silico Drug Discovery Market (by Country), 2018-2029
Figure 12.8: U.S. In-Silico Drug Discovery Market, 2018-2029
Figure 12.9: Canada In-Silico Drug Discovery Market, 2018-2029
Figure 12.10: Europe In-Silico Drug Discovery Market, 2018-2029
Figure 12.11: Europe: Market Dynamics
Figure 12.12: Europe In-Silico Drug Discovery Market (by Country), 2018-2029
Figure 12.13: Germany In-Silico Drug Discovery Market, 2018-2029
Figure 12.14: France In-Silico Drug Discovery Market, 2018-2029
Figure 12.15: U.K. In-Silico Drug Discovery Market, 2018-2029
Figure 12.16: Italy In-Silico Drug Discovery Market, 2018-2029
Figure 12.17: Spain In-Silico Drug Discovery Market, 2018-2029
Figure 12.18: Russia In-Silico Drug Discovery Market, 2018-2029
Figure 12.19: Rest-of-Europe In-Silico Drug Discovery Market, 2018-2029
Figure 12.20: Asia-Pacific In-Silico Drug Discovery Market, 2018-2029
Figure 12.21: APAC: Market Dynamics
Figure 12.22: APAC In-Silico Drug Discovery Market (by Country), 2018-2029
Figure 12.23: China In-Silico Drug Discovery Market, 2018-2029
Figure 12.24: Japan In-Silico Drug Discovery Market, 2018-2029
Figure 12.25: Australia In-Silico Drug Discovery Market, 2018-2029
Figure 12.26: India In-Silico Drug Discovery Market, 2018-2029
Figure 12.27: South Korea In-Silico Drug Discovery Market, 2018-2029
Figure 12.28: RoAPAC In-Silico Drug Discovery Market, 2018-2029
Figure 12.29: Latin America In-Silico Drug Discovery Market, 2018-2029
Figure 12.30: Latin America: Market Dynamics
Figure 12.31: Latin America In-Silico Drug Discovery Market (by Country), 2018-2029
Figure 12.32: Brazil In-Silico Drug Discovery Market, 2018-2029
Figure 12.33: Mexico In-Silico Drug Discovery Market, 2018-2029
Figure 12.34: Rest-of-Latin America In-Silico Drug Discovery Market, 2018-2029
Figure 12.35: RoW In-Silico Drug Discovery Market, 2018-2029
Figure 13.1: Total Number of Companies Profiled
Figure 13.2: Albany Molecular Research Inc.: Product Portfolio
Figure 13.3: Albany Molecular Research Inc.: SWOT Analysis
Figure 13.4: Certara USA, Inc.: Product Portfolio
Figure 13.5: Certara USA, Inc.: SWOT Analysis
Figure 13.6: Charles River: Overall Financials, 2016-2018
Figure 13.7: Charles River: Revenue (by Segment), 2016-2018
Figure 13.8: Charles River: SWOT Analysis
Figure 13.9: Chemical Computing Group ULC: Product Portfolio
Figure 13.10: Chemical Computing Group: SWOT Analysis
Figure 13.11: Collaborative Drug Discovery Inc.: Overall Product Portfolio
Figure 13.12: Collaborative Drug Discovery Inc.: SWOT Analysis
Figure 13.13: Dassault Systems (Biovia): Product Offerings
Figure 13.14: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 13.15: Evotec A.G. Company: Overall Financials, 2016-2018
Figure 13.16: Evotec A.G. Company: R&D Expenditure, 2016-2018
Figure 13.17: Evotec A.G. Company: SWOT Analysis
Figure 13.18: Product Portfolio: GVK Biosciences Private Limited
Figure 13.19: GVK Biosciences Private Limited SE.: SWOT Analysis
Figure 13.20: ICAGEN, INC.: Overall Product Portfolio
Figure 13.21: ICAGEN, INC.: Overall Financials, 2016-2018
Figure 13.22: ICAGEN, INC.: R&D Expenditure, 2016-2018
Figure 13.23: ICAGEN, INC.: SWOT Analysis
Figure 13.24: GE Healthcare: Product Portfolio
Figure 13.25: Novo Informatics Pvt. Ltd. Company: SWOT Analysis
Figure 13.26: Numerate Inc.: Overall Product Portfolio
Figure 13.27: Numerate Inc.: SWOT Analysis
Figure 13.28: PerkinElmer, Inc.: Product Portfolio for Global In-Silico Drug Discovery Market
Figure 13.29: PerkinElmer, Inc.: Overall Financials, 2016-2018
Figure 13.30: PerkinElmer, Inc.: Revenue (by Segment), 2016-2018
Figure 13.31: PerkinElmer, Inc.: Revenue (by Region), 2016-2017
Figure 13.32: PerkinElmer, Inc.: Revenue (by Region), 2018
Figure 13.33: PerkinElmer, Inc.: R&D Expenditure, 2016-2018
Figure 13.34: PerkinElmer, Inc.: SWOT Analysis
Figure 13.35: Schrödinger, LLC: SWOT Analysis
Figure 13.36: Selvita: Product Portfolio
Figure 13.37: Selvita: SWOT Analysis
Figure 13.38: Simulation Plus: Product Portfolio
Figure 13.39: Simulation Plus: Overall Financials, 2017-2019
Figure 13.40: Simulation Plus: Revenue (by Region), 2017-2019
Figure 13.41: Simulation Plus: R&D Expenditure, 2016-2018
Figure 13.42: Simulation Plus: SWOT Analysis
Figure 13.43: WuXi AppTec: Overall Financials, 2017-2019
Figure 13.44: WuXi AppTec: R&D Expenditure, 2016-2018
Figure 13.45: WuXi AppTec: SWOT Analysis
Figure 13.46: e-therapeutics plc: Product Portfolio
Figure 13.47: e-therapeutics plc: Overall Financials, 2017-2019